HC Wainwright Lifts Earnings Estimates for Solid Biosciences

Solid Biosciences Inc. (NASDAQ:SLDB) – Analysts at HC Wainwright raised their Q1 2026 earnings per share (EPS) estimates for shares of Solid Biosciences in a research report issued on Monday, March 23rd. HC Wainwright analyst A. He now forecasts that the company will earn ($0.35) per share for the quarter, up from their prior estimate of ($0.52). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for Solid Biosciences’ Q2 2026 earnings at ($0.35) EPS, Q3 2026 earnings at ($0.36) EPS, Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($1.43) EPS, FY2027 earnings at ($1.36) EPS, FY2028 earnings at ($0.60) EPS, FY2029 earnings at $0.89 EPS and FY2030 earnings at $1.81 EPS.

A number of other equities analysts have also weighed in on SLDB. Truist Financial raised shares of Solid Biosciences to a “strong-buy” rating in a research report on Wednesday. Guggenheim began coverage on Solid Biosciences in a research note on Friday, March 20th. They set a “buy” rating and a $26.00 price target on the stock. Chardan Capital reiterated a “buy” rating and set a $15.00 target price on shares of Solid Biosciences in a research report on Friday, March 20th. Wedbush reissued an “outperform” rating and issued a $14.00 price target on shares of Solid Biosciences in a research note on Wednesday, March 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Solid Biosciences in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Solid Biosciences has an average rating of “Moderate Buy” and an average target price of $16.09.

Solid Biosciences Trading Up 6.9%

Shares of SLDB stock opened at $7.73 on Wednesday. The company has a market capitalization of $602.24 million, a price-to-earnings ratio of -3.83 and a beta of 2.65. The firm has a 50-day moving average price of $6.57 and a 200 day moving average price of $5.84. Solid Biosciences has a twelve month low of $2.41 and a twelve month high of $8.72.

Solid Biosciences (NASDAQ:SLDB) last issued its quarterly earnings data on Thursday, March 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.01.

Institutional Trading of Solid Biosciences

A number of institutional investors have recently modified their holdings of the company. AQR Capital Management LLC purchased a new position in Solid Biosciences in the first quarter valued at approximately $418,000. Goldman Sachs Group Inc. grew its stake in Solid Biosciences by 32.2% during the first quarter. Goldman Sachs Group Inc. now owns 180,137 shares of the company’s stock worth $667,000 after buying an additional 43,910 shares during the period. Woodline Partners LP purchased a new stake in Solid Biosciences during the first quarter worth approximately $2,338,000. ProShare Advisors LLC acquired a new stake in shares of Solid Biosciences in the second quarter worth $80,000. Finally, Geode Capital Management LLC increased its position in shares of Solid Biosciences by 184.5% in the second quarter. Geode Capital Management LLC now owns 1,510,153 shares of the company’s stock worth $7,356,000 after acquiring an additional 979,294 shares in the last quarter. Hedge funds and other institutional investors own 81.46% of the company’s stock.

Insider Buying and Selling at Solid Biosciences

In related news, CEO Alexander Cumbo sold 16,644 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $5.82, for a total value of $96,868.08. Following the transaction, the chief executive officer directly owned 235,405 shares of the company’s stock, valued at approximately $1,370,057.10. This trade represents a 6.60% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO David T. Howton sold 7,469 shares of Solid Biosciences stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $5.82, for a total value of $43,469.58. Following the completion of the transaction, the chief operating officer owned 105,077 shares in the company, valued at $611,548.14. The trade was a 6.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 597,672 shares of company stock worth $3,816,546. 1.90% of the stock is currently owned by company insiders.

Key Stories Impacting Solid Biosciences

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Truist upgraded SLDB to “Strong‑Buy”, adding a near‑term positive catalyst that supports momentum and investor confidence. Zacks Article
• Positive Sentiment: JPMorgan raised its price target from $11 to $12 and maintained an “Overweight” rating — a ~55% upside vs. the current share level — which can attract institutional interest and buying. Benzinga Article
• Positive Sentiment: HC Wainwright raised multiple near‑term EPS estimates (Q1–Q4 2026) and materially improved its FY2026 outlook (from ~($2.12) to ($1.43)), while keeping a “Buy” rating and a $20 price target — signaling better expected near‑term performance and strong long‑term upside (FY2029–2030 turn to profitability). HC Wainwright Coverage
• Neutral Sentiment: Analyst optimism is concentrated in price targets and model revisions rather than new clinical readouts or revenue — the moves reflect expectations, not confirmed commercial progress; watch for upcoming company data or milestones to sustain gains. MarketBeat Summary
• Negative Sentiment: Consensus remains that Solid is not yet profitable (street FY current consensus still negative), so the stock is vulnerable to execution risk, trial setbacks, or any misses vs. these raised expectations. MarketBeat Financials

About Solid Biosciences

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.